Replimune stock.

The stock had previously closed at $10.40. Specifically, insider Konstantinos Xynos sold 7,313 shares of Replimune Group stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $10.92, for a total transaction of $79,857.96.Mar 30, 2022 · Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death and the ... Establishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.Dec 9, 2022 · In addition, Replimune has granted the underwriters a 30-day option to purchase up to an additional 1,436,172 shares of its common stock from Replimune at the public offering price, less the ... Replimune Group is now considered extended and out of buy range after clearing a 20.23 buy point in a first-stage cup with handle.See if the stock forms a new pattern or follow-on buying ...

Replimune Group stock has received a consensus rating of buy. The average rating score is and is based on 21 buy ratings, 0 hold ratings, and 0 sell ratings. What was the 52-week low for Replimune ...11.32. -0.21. -1.82%. WOBURN, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio ...We conduct our clinical trials with the highest possible standards. Replimune is also closely monitoring the ongoing COVID-19 pandemic to ensure patient safety. To download and learn more detailed information about Oncolytic Immunotherapy and RP1, click here. You can find more information about our ongoing clinical trials below.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added ...Replimune Group Enters Oversold Territory (REPL) Dividend Channel - Fri Feb 11, 4:10PM CST . Legendary investor Warren Buffett advises to be fearful when others are greedy, …

Nov 5, 2023 · To begin my analysis, Replimune's Q2 earnings revealed an upswing in expenditures, with R&D costs climbing 37% to $40.4M and SG&A expenses up 33% to $15.2M, culminating in a heightened operating ... Replimune Group, Inc. Common Stock (REPL) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.Find the latest Scholar Rock Holding Corporation (SRRK) stock quote, history, news and other vital information to help you with your stock trading and investing.Replimune is pioneering a new generation of cancer treatments called oncolytic immunotherapies. These cleverly designed therapeutics combine multiple mechanisms of action, enhancing the ability of viruses to replicate in and kill cancer cells, generating a powerful patient-specific, systemic immune response. Oncolytic immunotherapy enhances the ...

At Replimune, we are developing an emerging class of cancer treatments called oncolytic immunotherapies.­. Oncolytic immunotherapy has the potential to treat patients with a variety of tumor types and improve on existing immunotherapies. Our goal is to revolutionize cancer treatment by making personalized therapy a practical reality for all ...

To begin my analysis, Replimune's Q2 earnings revealed an upswing in expenditures, with R&D costs climbing 37% to $40.4M and SG&A expenses up 33% to $15.2M, culminating in a heightened operating ...

Historical daily share price chart and data for Replimune since 2018 adjusted for splits and dividends. The latest closing stock price for Replimune as of November 24, 2023 is 10.39.. The all-time high Replimune stock closing price was 52.65 on December 01, 2020.; The Replimune 52-week high stock price is 29.52, which is 184.1% above the current share …Replimune is pioneering a new generation of cancer treatments called oncolytic immunotherapies. These cleverly designed therapeutics combine multiple mechanisms of action, enhancing the ability of viruses to replicate in and kill cancer cells, generating a powerful patient-specific, systemic immune response. Oncolytic immunotherapy enhances the ... PURPOSE We evaluated the activity of intratumoral Coxsackievirus A21 (V937) in 57 patients with unresectable stage IIIC or IV melanoma. PATIENTS AND METHODS In this multicenter, open-label, phase II study, patients received up to a total V937 dose of 3 × 108 TCID50 (50% tissue culture infectious dose) in a maximum 4.0-mL …Christopher Sarchi REPL stock SEC Form 4 insiders trading. Christopher has made over 1 trades of the Replimune Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Christopher sold 5,255 units of REPL stock worth $57,385 on 16 November 2023.. The largest trade Christopher's ever made was selling 5,255 …With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.Replimune is advancing a pipeline of tumor-directed oncolytic immunotherapies derived from its RPx platform to fill unmet need across cancer types. RPx therapies are engineered using a proprietary HSV-1 strain and immune activating transgenes to maximize T cell stimulation and systemic immune activation. RP1 is designed to treat more immune ...

About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell …Earnings Summary. For their last quarter, Replimune Group (REPL) reported earnings of -$0.90 per share, missing the Zacks Consensus Estimate of -$0.80 per share. This reflects a negative earnings ...Replimune Group (REPL) BTIG analyst Kaveri Pohlman maintained a Buy rating on Replimune Group yesterday and set a price target of $60.00 . The company’s shares closed last Tuesday at $16.18 ...The stock of Replimune Group Inc (REPL) has gone up by 13.26% for the week, with a -15.10% drop in the past month and a -44.22% drop in the past quarter. The volatility ratio for the week is 7.61%, and the volatility levels for the past 30 days are 9.26% for REPL. The simple moving […]In other Replimune Group news, insider Pamela Esposito sold 5,358 shares of the business’s stock in a transaction on Monday, September 11th. The shares were sold at an average price of $20.01 ...Feb 24, 2023 · Replimune Group, Inc. (REPL) has been beaten down lately with too much selling pressure. While the stock has lost 14.6% over the past four weeks, there is light at the end of the tunnel as it is ... Earnings announcements can affect a stock's price. This table shows the stock's price the day before and the day after recent earnings reports, including the ...

Nov 18, 2023 · Christopher has made over 1 trades of the Replimune Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Christopher sold 5,255 units of REPL stock worth $57,385 on 16 November 2023. The largest trade Christopher's ever made was selling 5,255 units of Replimune Inc stock on 16 November 2023 worth over $57,385.

According to the issued ratings of 6 analysts in the last year, the consensus rating for Replimune Group stock is Buy based on the current 6 buy ratings for REPL. The average twelve-month price prediction for Replimune Group is $51.33 with a high price target of $70.00 and a low price target of $34.00. Learn more on REPL's analyst rating …Real time Replimune Group (REPL) stock price quote, stock graph, news & analysis.Replimune Group Inc. Watch list Set a price target alert After Hours Last Updated: Nov 29, 2023 4:02 p.m. EST Delayed quote $ 11.32 0.00 0.00% After Hours Volume: 16.73K Advanced Charting Volume:... Shares of Replimune have lost half of their value since my March 2021 update. Currently, in ROTY we own 8% portfolio weighting with 20% gain. ... The stock could also be impacted by negative ...Nov 3, 2022 · About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death ... Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA. REPL - Replimune Group Inc - Stock screener for ...

Oct 15, 2020 · Shares of Replimune Group ( REPL -2.97%) were soaring 13.3% higher as of 11:01 a.m. EDT on Thursday after rising as much as 22.4% earlier in the day. The big jump resulted from the company's ...

Replimune’s tumor-directed oncolytic immunotherapies have the potential to redefine the cancer treatment paradigm. Replimune’s approach brings together multiple mechanisms of action to destroy the tumor, ignite an anti-cancer response, and generate long-lived immune activity. The ultimate aim is to improve outcomes for patients with cancer. Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added ... May 18, 2023 · Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death and the ... BMO Capital Markets raised the price target on Replimune Group Inc (NASDAQ: REPL) to $40 from $30 on a bullish view into upcoming data readouts for lead asset RP1 in melanoma and cutaneous ...Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.Nov 30, 2023 · Replimune Group stock has received a consensus rating of buy. The average rating score is and is based on 21 buy ratings, 0 hold ratings, and 0 sell ratings. What was the 52-week low for Replimune ... Replimune’s tumor-directed oncolytic immunotherapies have the potential to redefine the cancer treatment paradigm. Replimune’s approach brings together multiple mechanisms of action to destroy the tumor, ignite an anti-cancer response, and generate long-lived immune activity. The ultimate aim is to improve outcomes for patients with cancer.Item 1. Description of Registrant’s Securities to be Registered. A description of the common stock of Replimune Group, Inc. (the “Registrant”), par value $0.001 per share, to be registered hereunder is set forth under the caption “Description of capital stock” in the prospectus that constitutes a part of the Registrant’s Registration Statement on Form S …

Find the latest Replimune Group, Inc. (REPL) stock analysis from Seeking Alpha's top analysts: exclusive research and insights from bulls and bears.18 Sep 2023 ... at Replimune and Gilead also shared how they're accelerating ... Veeva (VEEV stock) Exceptional Business! SaaS Growth Stock for Life Sciences ...Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company’s proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively ...2 days ago · What is the target price for Replimune Group (REPL) stock? A The latest price target for Replimune Group ( NASDAQ : REPL ) was reported by HC Wainwright & Co. on Monday, November 13, 2023 . Instagram:https://instagram. stock news alertsbroker currency tradingsilver mining etfnatural gas stock companies Shares of Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) have been given an average rating of “Buy” by the six research firms that are presently covering the firm, MarketBeat.com reports.Six equities research analysts have rated the stock with a buy recommendation. The average 12 month price target among brokerages that have … a i companies to invest inprofit options calculator See Replimune Group, Inc. stock price prediction for 1 year made by analysts and compare it to price changes over time to develop a better trading strategy. ... Based on 10 analysts giving stock ratings to REPL in the past 3 months. EPS. … atm withdrawal limit td bank Replimune Group, Inc. (REPL) NasdaqGS - NasdaqGS Real Time Price. Currency in USD. Follow. 2W 10W 9M. 11.71 +0.53 (+4.74%) At close: 04:00PM EST. 11.71 0.00 (0.00%) After hours: 04:20PM EST.Stock Price. $14.2. 2023-11-03. Market Capitalization. $837.7 M. 2023-11-03. Replimune Summary. Company Summary. Overview. Replimune is developing novel, proprietary oncolytic immunotherapies intended to improve both the direct anti-tumor effects of selective virus replication and the potency of the immune response to the tumor antigens ...Stocks trading online may seem like a great way to make money, but if you want to walk away with a profit rather than a big loss, you’ll want to take your time and learn the ins and outs of online investing first. This guide should help get...